HGH Fragment 176-191
AOD-9604 · AOD9604 · Tyr-hGH(177-191) · Lipolytic Fragment · Frag 176-191
Last updated
At a glance
Overview
HGH Fragment 176-191 (sold clinically as AOD-9604) is the C-terminal lipolytic tail of human growth hormone — the fat-burning signal without the IGF-1, the water retention, the glucose disturbance, or the HPTA interactions. That profile is exactly why it stays in rotation for physique-focused users who want a clean, non-stimulant lipolytic they can bolt onto a cut without touching thyroid, catecholamines, or the GH axis proper.
People running it fall into three camps: contest-prep bodybuilders layering it over a GH/GHRP stack to squeeze more lipolysis without pushing IGF-1 higher, looksmaxxers and recomp-focused users who want a PCT-safe fat-loss adjunct that doesn't thrash sleep or heart rate, and women who need something non-androgenic that plays nicely with everything else in the stack. It is genuinely one of the safest peptides in the catalog — repeated-dose human trials showed an adverse-event profile indistinguishable from placebo, with no change in IGF-1, fasting glucose, or OGTT.
"AOD9604 was well tolerated, with no differences in adverse event profile, fasting glucose, OGTT, or IGF-1 levels compared to placebo after repeated administration in humans." — Stier et al., J Endocrinol Metab (2013)
The honest trade-off: efficacy is modest. The Phase IIb obesity trial landed around 2.6 kg over 12 weeks at 1 mg/day — real, but not transformative, and community dose escalation above that has no evidence behind it. Frag is a precision adjunct, not a headline fat-loss compound.
This guide covers the dosing ladder (clinical 1 mg/day vs. the split-dose community protocol), the fasted-cardio stubborn-fat protocol that defines its best use case, how to stack it with GH secretagogues, GLP-1 agonists, T3, and yohimbine, the side-effect profile and why it earns its "clean" reputation, and the realistic fat-loss expectations to set prior to initiating a protocol.
How HGH Fragment 176-191 works
HGH Fragment 176-191 is the synthetic C-terminal lipolytic domain of human growth hormone — specifically amino acids 176–191, with the clinically developed AOD-9604 variant adding an N-terminal tyrosine for stability. It keeps the fat-mobilizing activity of native GH while stripping out the somatogenic, IGF-1-driving, and glucose-disrupting effects. That separation is the entire point of the molecule.
Selective Lipolysis Without GH-Receptor Somatogenic Signaling#
The fragment does not meaningfully activate the GH receptor's JAK2/STAT5 growth axis. IGF-1 stays flat, fasting glucose stays flat, and OGTT is unchanged — the exact opposite of what you see on recombinant GH.
"AOD9604 was well tolerated, with no differences in adverse event profile, fasting glucose, OGTT, or IGF-1 levels compared to placebo after repeated administration in humans." — Stier H, Vos E, Kenley D, J Endocrinol Metab, 2013
Practically, this is why Frag stacks cleanly with AAS, SARMs, real GH, GLP-1 agonists, T3, and clen without compounding insulin resistance, carpal tunnel, or water retention. It's a lipolytic tool, not a hormonal one.
β3-Adrenergic Receptor Upregulation in Adipose Tissue#
The fragment's chronic fat-loss effect routes through β3-AR expression in white adipose tissue. β3 is the adrenergic subtype that actually matters for fat oxidation in humans, and upregulating it sensitizes adipocytes to catecholamine-driven lipolysis.
"AOD9604 up-regulated β3-adrenergic receptor gene expression in adipose tissue, and chronic effects on body weight and fat reduction were lost in β3-AR knock-out mice." — Heffernan M, Summers RJ, Thorburn A, et al., Endocrinology, 2001
This is the mechanistic rationale for the standard community protocol: dose fasted pre-cardio, optionally with caffeine or yohimbine, so elevated circulating catecholamines hit a more responsive β3 receptor population. Without the adrenergic driver (i.e. sitting fed on the couch), the lipolytic signal is much weaker.
Direct Lipolysis and Anti-Lipogenic Activity#
Beyond the β3 pathway, the fragment acts directly on adipocytes and hepatocytes to shift the lipogenesis/lipolysis balance. It stimulates hormone-sensitive lipase activity while suppressing acetyl-CoA carboxylase — the rate-limiting enzyme for de novo fatty acid synthesis.
"Results indicated that the synthetic fragment potently suppressed lipogenesis and stimulated lipolysis in both adipose tissue and hepatocytes." — Heffernan MA, Jiang WJ, Thorburn AW, Ng FM, Am J Physiol Endocrinol Metab, 2000
In plain terms: more triglyceride coming out of storage, less new fat being laid down. The caveat every experienced user learns — liberated free fatty acids that aren't oxidized just get re-esterified back into adipose. Frag needs a caloric deficit and ideally aerobic work downstream of the injection, or the lipolysis is wasted.
Non-Hyperglycemic, Non-Diabetogenic Profile#
Native GH's well-known downside is that it antagonizes insulin and pushes fasting glucose up, especially at bodybuilding doses. The 176–191 fragment is specifically the region that retained lipolytic activity when the diabetogenic and growth-promoting regions were mapped out and discarded.
"The data suggest that AOD9604 and its analogs have potential as selective, non-hyperglycemic lipolytic agents distinct from native hGH." — Ng FM, Sun J, Sharma L, et al., Horm Res, 2000
This is why Frag is the go-to lipolytic for users already running insulin, GH, or a GLP-1 — it won't stack on top of existing glucose pressure, and it won't blunt insulin sensitivity on a cut.
Pharmacokinetic Consequences for Dosing#
Plasma half-life is short (~30 minutes), cleared by peptidase degradation and renal elimination. The downstream effects on β3-AR expression and HSL activity outlast the peptide itself, but free-fatty-acid flux tracks the injection window closely. That's the mechanistic argument for split dosing — AM fasted pre-cardio plus pre-bed, with a third pre-workout shot on advanced cut protocols — rather than the single daily dose used in the clinical program. You're not chasing a higher peak; you're extending the lipolytic window across the day.
The net read: Frag is a selective, non-hormonal lipolytic with a clean safety profile and a real but modest effect size. It's a scalpel for a cut, not a hammer — best used as an adjunct to a deficit and adrenergic stimulus rather than as a standalone fat-loss driver.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 250–500 mcg | Twice daily | Documented entry-level range |
| Mid | 500–1000 mcg | Twice daily | Most commonly studied range |
| High | 1000–1500 mcg | Twice daily | Short half-life rewards split dosing — typically AM fasted (pre-cardio) and pre-bed. Advanced cut protocols add a third pre-workout dose. Clinical trials used 1 mg once daily; community practice splits to extend lipolytic window. |
Cycle length & outcomes
Documented cycle
8–16 weeks
Plateau after
12 wks
HGH Fragment 176-191 is non-hormonal, non-suppressive, and has no feedback loop to desensitize — which means no loading phase, no taper, no PCT, and no mandatory off-time. Cycle length is driven almost entirely by the cut timeline, not by the peptide's pharmacology.
Cycle Length by Goal#
| Goal | Cycle Length | Daily Dose | Frequency |
|---|---|---|---|
| First run / tolerance check | 4–6 weeks | 250 mcg | Once daily, AM fasted |
| Standard cut (intermediate) | 8–12 weeks | 500–1000 mcg | Split AM fasted + pre-bed |
| Contest prep / stubborn fat | 10–16 weeks | 1000–1500 mcg | Split 3× (AM / pre-cardio / pre-bed) |
| Year-round maintenance (on TRT/blast) | Continuous | 250 mcg | Once daily, AM fasted |
| Female cut | 8–12 weeks | 125–500 mcg | Split AM + pre-bed |
Onset and What to Expect#
Lipolysis kicks in within the first dose — free fatty acids mobilize in the ~30 min window post-injection, which is why fasted-cardio timing matters. Visible composition change typically shows up around week 3–4 of consistent dosing in a real caloric deficit. Expect a slow grind: realistic fat loss attributable to the fragment itself is in the 0.3–0.5 lb/week range, layered on top of whatever your diet and training are already producing. If you're expecting GLP-1 or tesamorelin magnitudes, you have the wrong compound.
"AOD9604 was well tolerated, with no differences in adverse event profile, fasting glucose, OGTT, or IGF-1 levels compared to placebo after repeated administration in humans." — Stier, Vos & Kenley, J Endocrinol Metab (2013)
Loading and Tapering#
Neither is necessary. The Phase IIb program dosed 1 mg SC daily from day one with no ramp, and community practice confirms there's no benefit to titrating up. You also don't taper off — stop when the cut is done. There's no rebound, no suppression to recover from, and IGF-1 doesn't move in either direction.
"Results indicated that the synthetic fragment potently suppressed lipogenesis and stimulated lipolysis in both adipose tissue and hepatocytes." — Heffernan et al., Am J Physiol Endocrinol Metab (2000)
Split Dosing Logic#
The ~30-minute plasma half-life is the single most important PK fact for protocol design. Clinical trials used 1 mg once daily and still produced measurable fat loss, because the downstream β3-adrenergic receptor upregulation outlasts the peptide itself:
"AOD9604 up-regulated β3-adrenergic receptor gene expression in adipose tissue, and chronic effects on body weight and fat reduction were lost in β3-AR knock-out mice." — Heffernan et al., Endocrinology (2001)
That said, community practice splits the daily dose to keep free fatty acid flux elevated across multiple fasted windows — most users report better subjective results on a 2×/day split than the same total dose given once. Three injections per day is contest-prep territory and probably past the point of diminishing returns; there's no evidence 1.5 mg/day beats 1 mg/day.
Bloodwork Cadence#
Frag itself requires no bloodwork. It doesn't move IGF-1, fasting glucose, HbA1c, lipids, LH/FSH, or liver markers. If you're running it as part of a larger stack — GH, tesamorelin, CJC/ipamorelin, AAS, T3, GLP-1s — have the standard cycle panel drawn (CBC, CMP, lipids, IGF-1, HbA1c) at baseline and every 8–12 weeks for those compounds. The fragment doesn't add anything you need to monitor.
Stacking Timing#
- With GH or GHRP stack: Frag AM fasted (pre-cardio), GH/GHRP pre-bed. Keeps the lipolytic windows separated and stacks β3-AR upregulation with GH-driven lipolysis.
- With GLP-1 (sema/tirz/reta): No timing conflict. Run Frag normally; the GLP-1 does most of the work on appetite and the Frag adds a direct lipolytic vector on training days.
- With clen or yohimbine: Dose Frag 15–30 min pre-cardio to exploit catecholamine synergy on the upregulated β3 receptors. This is the strongest mechanistic case for stacking.
- With AAS cut cycles: No interaction. Slot Frag wherever it fits your schedule.
When to Stop#
Run it as long as the cut runs. There's no biological clock on this peptide — no receptor desensitization signal has been documented, efficacy doesn't meaningfully decay across a 12-week window in the clinical data, and there's no recovery phase to plan. When you hit your target condition or transition to a surplus, just stop. Maintaining a low-dose 250 mcg AM maintenance dose year-round through bulks, that's a reasonable and well-tolerated protocol — just don't expect it to do much without a deficit underneath it.
Body Transformation Preview
Lean Mass Gain
0.0 lbs
0.0–0.0 lbs range
Fat Loss
5.4 lbs
4.0–6.7 lbs range
Fat Loss by Week
Risks & mistakes
Common (most users)#
- Injection-site redness, itching, or minor bruising — the most frequent complaint by a wide margin. Rotate between abdomen, flank, and thigh; pinch a clean SC fold; use fresh 29–31G insulin pins. Warming the reconstituted vial in your hand for 30 seconds before drawing reduces sting.
- Transient mild fatigue or flushing in the first few doses — usually resolves within the first week. No dose adjustment needed.
- Mild injection-site lumpiness from repeated dosing in the same spot — rotate sites and avoid injecting into the same quadrant twice in 48 hours.
- Nothing else, realistically. Repeated-dose human trials found the adverse event profile indistinguishable from placebo, with no change in fasting glucose, OGTT, or IGF-1.
"AOD9604 was well tolerated, with no differences in adverse event profile, fasting glucose, OGTT, or IGF-1 levels compared to placebo after repeated administration in humans." — Stier H, Vos E, Kenley D, J Endocrinol Metab (2013)
Uncommon (dose-dependent or individual)#
- Mild headache — reported anecdotally at higher split doses (1.5 mg/day community protocols). Back off to 500–1000 mcg/day and reassess; usually not dose-limiting.
- Transient hunger shifts — some users report either suppressed or mildly increased appetite in the first 1–2 weeks. Neither is clinically significant; rides out.
- Flat response / "nothing happened" — not a side effect per se, but common enough to flag. Usually traces to (a) underdosed or mis-sequenced vendor product, (b) no actual caloric deficit, or (c) unrealistic expectations of GH-like recovery and sleep effects that Frag simply does not produce.
- Bloodwork to monitor if stacked: Frag itself doesn't require labs. If you're running it alongside GH, GHRPs, or insulin, track IGF-1, fasting glucose, and HbA1c every 8–12 weeks for the stack — not for the Frag.
Rare but serious#
- True hypersensitivity reactions (urticaria, angioedema, respiratory involvement) — vanishingly rare, not documented in published trials, but possible with any injectable peptide. Stop immediately and seek care if you see hives, lip/tongue swelling, or wheezing.
- Persistent injection-site nodules or sterile abscesses — almost always a reconstitution hygiene or contaminated-vendor issue, not the peptide itself. Discard the vial, improve technique, source elsewhere.
- No anti-drug antibody formation was detected in Phase II trial subjects, and no case reports of immunogenic reactions have surfaced in community use.
"The data suggest that AOD9604 and its analogs have potential as selective, non-hyperglycemic lipolytic agents distinct from native hGH." — Ng FM, Sun J, Sharma L, et al., Horm Res (2000)
Hard contraindications#
- Active malignancy — theoretical rather than demonstrated, but any lipolytic agent mobilizes substrate that tumor metabolism can use. Preclinical work has specifically explored Frag as a targeting ligand for doxorubicin delivery into breast cancer cells, implying receptor-level interaction with at least some tumor lines. Don't run it with active or recent cancer.
- Pregnancy and lactation — no safety data, no reason to experiment.
- Known peptide hypersensitivity — prior reaction to Frag or to structurally related GH fragments.
Notably not on this list, because the pharmacology genuinely supports it: diabetes/insulin resistance (no glucose disturbance), AAS cycles (no hormonal interaction), GLP-1 stacks (no interaction), stimulant fat burners (no interaction), thyroid meds (no interaction).
Gender, PCT, and population notes#
Frag is non-hormonal, non-androgenic, and non-virilizing. Women run 125–250 mcg SC 1–2× daily with no concern for voice changes, clitoral hypertrophy, cycle disruption, or any of the other flags that apply to AAS. It does not cross the HPTA in either sex — no PCT is required, no suppression to recover from, no AI or SERM interaction. It's one of the cleanest adjuncts available for a "hold muscle, shed fat" PCT phase or a TRT-only recomp, precisely because it sits completely outside the endocrine conversation. Safe to continue uninterrupted year-round as a low-dose maintenance lipolytic during bulks.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.05 | ×1.22 | ×1.00 | |
| synergistic | ×1.00 | ×1.20 | ×1.05 |
FAQ — HGH Fragment 176-191
Research & citations
5 studies cited on this page.
Conclusion
HGH Fragment 176-191 (AOD-9604) sits in a unique spot for users looking for a non-stimulant, non-hormonal fat-loss peptide that plays well with just about any stack. While its effect size is modest, the safety and flexibility keep it popular as a clean adjunct to more aggressive protocols.
Key takeaways:
- Typical dose: 250–500 µg subQ, 1–2× daily (AM fasted and/or pre-bed)
- Advanced protocols reach 1,000–1,500 µg split into two or three daily doses during dedicated cuts
- Best run 8–16 weeks; no HPTA suppression, PCT, or cycling off required
- Safe for women at 125–250 µg 1–2× daily — no androgenic or IGF-1 activity to worry about
- Stacks well with GH, GHRPs, GLP-1s (semaglutide, tirzepatide), T3, or stimulant fat-burners
- Headline benefit: mild, steady fat loss (~0.4–0.5 lb/week) with an exceptionally low side effect profile
For those seeking a gentle, hands-off lipolytic edge without stimulants, androgenic risk, or metabolic chaos, HGH Frag is a solid plug-and-play tool. Just keep realistic expectations — it works best as an additive, not a centerpiece.